Protein Helps Neurons Maintain Dopamine Production in Models of Parkinson's Disease
|
By LabMedica International staff writers Posted on 20 Oct 2016 |

Image: Diagram shows how the neuropeptide Prokineticin-2 (PK2) is rapidly induced during early stages of neurotoxic stress and secreted into extracellular spaces. PK2 is thought to act as a protective mechanism that helps neurons cope with Parkinson’s disease (Photo courtesy of Dr. Anumantha Kanthasamy, Iowa State University).
A team of neurodegenerative disease researchers has identified a protein that seems to help neurons in the brain maintain dopamine production.
Investigators at Iowa State University (Ames, USA) have been studying Prokineticin-2 (PK2), a recently discovered secreted protein that regulates important physiological functions including olfactory biogenesis and circadian rhythms in the central nervous system.
They reported in the October 5, 2016, online edition of the journal Nature Communications that although in mouse models PK2 expression was low in the nigral system of the brain, its receptors were constitutively expressed on nigrostriatal neurons, and that PK2 expression was highly induced in nigral dopaminergic neurons during early stages of degeneration in multiple mouse models of Parkinson’s disease (PD).
Functional studies demonstrated that PK2 promoted mitochondrial biogenesis and activated ERK (Extracellular signal-regulated kinase) and Akt (Protein kinase B) survival signaling pathways, thereby driving neuroprotection. Importantly, PK2 overexpression was protective, whereas PK2 receptor antagonism exacerbated dopaminergic degeneration in experimental PD.
PK2 signaling protected against oxidative stress, mitochondrial dysfunction, and dopaminergic degeneration. Blocking PK2 signaling using a PK2 receptor antagonist increased dopaminergic degeneration in a PD mouse model, while overexpression of PK2 by adeno-associated virus (AAV) gene delivery was neuroprotective. PK2 expression was also found to be elevated in the substantia nigra (SN) of PD patients, corroborating PK2’s clinical relevance in human PD.
“Of the thousands and thousands of factors we tracked in our experiments, why was this protein expressed so highly?” said senior author Dr. Anumantha Kanthasamy, professor of veterinary medicine at Iowa State University. “The neurons use PK2 to cope with stress. It is an in-built protective mechanism.”
Related Links:
Iowa State University
Investigators at Iowa State University (Ames, USA) have been studying Prokineticin-2 (PK2), a recently discovered secreted protein that regulates important physiological functions including olfactory biogenesis and circadian rhythms in the central nervous system.
They reported in the October 5, 2016, online edition of the journal Nature Communications that although in mouse models PK2 expression was low in the nigral system of the brain, its receptors were constitutively expressed on nigrostriatal neurons, and that PK2 expression was highly induced in nigral dopaminergic neurons during early stages of degeneration in multiple mouse models of Parkinson’s disease (PD).
Functional studies demonstrated that PK2 promoted mitochondrial biogenesis and activated ERK (Extracellular signal-regulated kinase) and Akt (Protein kinase B) survival signaling pathways, thereby driving neuroprotection. Importantly, PK2 overexpression was protective, whereas PK2 receptor antagonism exacerbated dopaminergic degeneration in experimental PD.
PK2 signaling protected against oxidative stress, mitochondrial dysfunction, and dopaminergic degeneration. Blocking PK2 signaling using a PK2 receptor antagonist increased dopaminergic degeneration in a PD mouse model, while overexpression of PK2 by adeno-associated virus (AAV) gene delivery was neuroprotective. PK2 expression was also found to be elevated in the substantia nigra (SN) of PD patients, corroborating PK2’s clinical relevance in human PD.
“Of the thousands and thousands of factors we tracked in our experiments, why was this protein expressed so highly?” said senior author Dr. Anumantha Kanthasamy, professor of veterinary medicine at Iowa State University. “The neurons use PK2 to cope with stress. It is an in-built protective mechanism.”
Related Links:
Iowa State University
Latest BioResearch News
- D-Serine May Predict Immune Checkpoint Therapy Resistance in Gastric Cancer
- New Genetic Cause Identified for Neurodevelopmental Disorder
- New Genetic Discovery Could Support Precision Diabetes Care
- Inherited Genetic Differences Help Explain Variable CAR T-Cell Therapy Outcomes
- AI-Powered Genome Mapping Reveals New Layer of Alzheimer’s Disease Biology
- Genetic Variations Reveal Mechanisms Behind Sudden Cardiac Death Risk
- Immune Biomarkers Support Early Risk Stratification in Oral Precancer
- Global Genetic Map Identifies Regional Parkinson’s Variants to Support Diagnostics
- Breakthrough Genetic Map Advances Understanding of Bone Disorders
- Study Identifies Hereditary Subtype of Aggressive Prostate Cancer
- Gene Variants Linked to Pollution-Exacerbated Asthma
- Single-Cell Analysis Mapping Links Inflammation Response to Acute Myeloid Leukemia
- Study Reveals New Insights into Rare Blood Cancer Development
- New Findings Clarify Molecular Drivers of Rare Small Intestinal Cancer
- Lung Cancer Study Reveals Cellular Program Behind Therapy Resistance
Channels
Clinical Chemistry
view channel
Rapid Breath Sensor Detects SARS-CoV-2 from Exhaled Air
Nasal swabs and polymerase chain reaction (PCR) testing have been central to identifying SARS-CoV-2, but they can be uncomfortable, slow, and logistically complex when samples require transport.... Read more
Head-to-Head Study Compares Blood Tests for Early Alzheimer’s Disease Detection
Accurate, scalable diagnostics are becoming increasingly important as disease-modifying therapies reshape Alzheimer’s disease care, yet many patients still rely on invasive cerebrospinal fluid sampling... Read more
Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy
Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read moreMolecular Diagnostics
view channel
Comprehensive Genomic Testing Expands Treatment Options for Advanced Cancers
Selecting effective therapies for advanced cancers remains difficult because standard tumor testing often targets only a limited set of genes. As options dwindle, many patients face decisions without strong... Read more
Multi-Omics Analysis Identifies Additional Risk Genes in Hereditary Breast and Ovarian Cancer
Hereditary breast and ovarian cancer can be difficult to explain genetically, leaving many high-risk families without clear answers. Although 13 established risk genes, including BRCA1 and BRCA2, are routinely... Read more
Machine Learning Approach Expands Epigenetic Testing for Prenatal Genetic Disorders
Prenatal genetic testing is increasingly used to identify potential neurodevelopmental conditions, but results often include variants of uncertain significance that clinicians cannot confidently classify.... Read more
New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples
Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read moreHematology
view channel
New Genetic Findings Reveal Cause of Bone Marrow Failure Syndrome
Inherited bone marrow failure syndromes (IBMFS) impair the bone marrow’s ability to produce sufficient healthy blood cells and are associated with an increased risk of early-onset myelodysplastic syndromes (MDS).... Read more
Ultra-Portable Device Enables Finger-Prick Blood Testing at Home
Patients who need frequent blood tests often face repeated clinic visits that burden services and disrupt care. In the UK, millions of tests are performed each year to diagnose disease, guide therapy,... Read moreImmunology
view channel
Immune Biomarkers May Predict Recurrent Checkpoint Inhibitor Arthritis
Inflammatory arthritis is a recognized immune-related adverse event in patients treated with immune checkpoint inhibitors (ICIs) for cancer. Between 20% and 50% of affected patients experience more than... Read more
Immune Cell Blood Test May Predict Melanoma Immunotherapy Response
Melanoma remains one of the deadliest skin cancers, although outcomes improve markedly when the disease is detected early. Immunotherapy has extended survival for many patients with advanced melanoma,... Read moreMicrobiology
view channel
Genetic Marker Identifies Emerging Resistance to Frontline Malaria Drugs
Artemisinin-based combination therapy remains central to controlling Plasmodium falciparum malaria, but emerging drug resistance is complicating treatment and surveillance. In Uganda and across sub-Saharan... Read more
Surveillance and Susceptibility Testing Track Rising Candida Auris in U.S.
Drug-resistant fungal infections are straining infection control and treatment in hospitals and long-term care facilities, where rapid transmission can lead to severe outcomes. Candida auris has expanded... Read morePathology
view channel
30-Minute 3D Histology Tool Supports Intraoperative Glioma Margin Assessment
Glioma surgery depends on distinguishing infiltrative tumor from functional brain tissue, but microscopic spread beyond visible margins makes this difficult. Conventional frozen sections provide rapid... Read more
AI Links Organ-Specific Aging Patterns in Histology to Blood-Based Signals
Clinical decisions often rely on chronological age, yet organs can age biologically at different rates that remain hard to assess. Noninvasive detection of organ-specific aging could support disease monitoring... Read moreTechnology
view channel
Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
Proteotype Diagnostics has introduced Alchemi, a proprietary data and clinical workflow platform being developed for Enlighten, the company’s investigational blood-based multi-cancer test.... Read more
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Strategic Collaboration Expands Commercial Access to Oncology Companion Diagnostics
CellCarta, a global CRO laboratory serving the biopharmaceutical industry, has announced a strategic collaboration with Tempus AI to broaden access to companion diagnostics (CDx) in oncology.... Read more







